Vogt–Koyanagi–Harada syndrome – current perspectives

Abstract

Abeir Baltmr,1 Sue Lightman,1,2 Oren Tomkins-Netzer1–3 1Uveitis Service, Moorfields Eye Hospital, London, UK; 2Department of Clinical Ophthalmology, UCL Institute of Ophthalmology, London, UK; 3Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel Abstract: Vogt–Koyanagi–Harada syndrome is a cause of noninfectious panuveitis, leading to significant vision loss in many patients. It is an autoimmune disease occurring in genetically susceptible individuals and clinically presents as bilateral panuveitis with serous retinal detachments and hyperemic, swollen optic discs, which are associated with neurological and auditory manifestations. Early diagnosis and prompt and adequate treatment with immunosuppressive agents (corticosteroids and other immunosuppressive drugs) may halt disease progression and prevent recurrences and vision loss. This review summarizes the current knowledge on the variable clinical aspects of this disease, highlighting diagnostic and treatment strategies. Keywords: multifocal choroiditis, serous retinal detachment, panuveitis, sunset glow fundus, starry sky, corticosteroid

Keywords

• Vogt–Koyanagi–Harada disease (VKH)
• serous retinal detachment
• panuveitis
• sunset glow fundus
• starry sky